All In Biotech

Free tool

FAERS Monitor: Pluvicto

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215833 or its brand name (Pluvicto, Lutetium Lu-177 Vipivotide Tetraxetan). Reports on generic versions are filed under their own applications.

Reports

13,841

Serious

3,364

24% of reports

Hospitalization

725

Death reported

1,680

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • general physical health deterioration6,684
  • ill-defined disorder3,641
  • death1,321
  • disease progression360
  • malignant neoplasm progression343
  • prostatic specific antigen increased287
  • laboratory test abnormal266
  • fatigue238
  • anaemia204
  • platelet count decreased168
  • hormone-refractory prostate cancer167
  • illness165
  • haemoglobin decreased159
  • thrombocytopenia147
  • covid-19146

Reports by year received

View as table
YearReports
20161
2022622
20233,535
20243,984
20253,457
20262,242

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,318 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hormone-refractory prostate cancerSignal167248.6211.335,189
ill-defined disorderSignal3,64196.894.0325,422
general physical health deteriorationSignal6,68493.191.4576,936
prostatic specific antigen increasedSignal28732.328.88,501
laboratory test abnormalSignal26613.812.33,125
malignant neoplasm progressionSignal3435.14.61,129
disease progressionSignal3604.64.21,025
illnessSignal1652.42.1139
platelet count decreasedSignal1682.42.1136
haemoglobin decreasedSignal1592.42.0123
deathSignal1,3212.32.21,045
thrombocytopenia1472.01.773
anaemia2041.61.449
covid-191461.31.18
fatigue2380.50.4152

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.